(2S)-1-[2-[(1-Ethoxycarbonyl-3-Phenyl-Propyl)Amino]Propanoyl]Pyrrolidine-2-Carboxylic Acid

The synthetic dipeptide carboxyalkyl diacid designated as (2S)-1-[2-[(1-ethoxycarbonyl-3-phenylpropyl)amino]propanoyl]pyrrolidine-2-carboxylic acid—more commonly referenced as enalapril in its free acid form—constitutes the active pharmacophoric scaffold of one of the most extensively prescribed angiotensin-converting enzyme (ACE) inhibitor prodrugs. With a molecular formula of C₂₀H₂₈N₂O₅ and a molecular weight of 376.45 g/mol, the compound is commercially handled almost exclusively as the maleate salt (CAS 76095-16-4) to enhance crystallinity and oral bioavailability. Enalapril maleate is recognized in all major pharmacopoeias, including the United States Pharmacopeia (USP-NF 2023 monograph), the European Pharmacopoeia (Ph. Eur. 10.8), and the Japanese Pharmacopoeia (JP XVIII), and it serves as the reference standard for generic oral solid dosage forms targeting hypertension and chronic heart failure. The intact ester moiety mandates hepatic carboxylesterase-mediated hydrolysis to yield enalaprilat, the potent zinc-coordinating inhibitor responsible for blockade of angiotensin II formation, with an in vitro Ki at the C-domain of somatic ACE reported in the low nanomolar range. Unlike direct-acting ACE inhibitors such as lisinopril, this pro-moiety imparts a kinetic delay that attenuates first-dose hypotension but also introduces a dependency on intact hepatocellular function for pharmacological activation. The following sections detail the compendial identity and purity envelope, process-specific considerations for solid dosage manufacture, and a structurally anchored differentiation from alternative ACE inhibitor classes.

What Are the Compendial Specifications for Enalapril Maleate API?

The monographed acceptance criteria for enalapril maleate API reflect a multi-laboratory consensus on quality attributes that ensure therapeutic equivalence across manufacturing sources. A high-level specification table, drawn from harmonized USP and Ph. Eur. monographs, is provided below. All numeric thresholds represent the limits as published in the current editions unless otherwise noted.

The specifications above constitute the minimal pharmacopeial framework. Critical production-batch release additionally includes polymorphic verification by X-ray powder diffraction (XRPD) against the Form I reference pattern, because enalapril maleate crystallizes as a stable monoclinic form whose amorphization during high-shear mixing can accelerate hydrolytic degradation. Suppliers of direct-compression processable enalapril maleate often furnish a micronized grade with a defined span [(D₉₀−D₁₀)/D₅₀] ≤2.5 to minimize segregation potential in low-dose (2.5–20 mg) tablet blends containing mannitol or microcrystalline cellulose as the major filler. Water content is stringently controlled not only for hydrolytic stability but because residual moisture above 0.8% profoundly reduces the Tg of amorphous domains generated during milling, leading to caking in the intermediate bulk container during storage at 25°C/60% RH per ICH Q1A(R2) stability protocols.

Without a heading to separate, the discussion transitions directly into practical formulation behavior observed in solid dosage manufacturing. Enalapril maleate at the 10 mg dose exhibiting a BCS Class 3 designation under FDA biowaiver criteria poses distinct challenges when blended with common disintegrants such as croscarmellose sodium. In a direct compression regimen employing a rotary tablet press with a compression force of 8–15 kN and a turret speed of 60 rpm, the lamination tendency of convex-faced 6 mm round punches becomes measurable when the powder feed frame dwell extends beyond 45 seconds. The root cause is an electrostatic charge accumulation driven by the triboelectric series position of the micronized maleate salt against stainless steel (316L) feed hoppers, which can be mitigated by a pre-blending step with 0.5% w/w colloidal silicon dioxide (AEROSIL 200 Pharma) and an equilibration period of 12–24 hours at ≤30% RH prior to lubrication. In-line NIR monitoring of blend uniformity at a sampling interval of 10 seconds during the press run has demonstrated that batches meeting a relative standard deviation of ≤3.0% in API content uniformity (USP <905> acceptance value ≤15.0) are consistently achievable when the micronized grade is incorporated via a low-shear tumble blender at 75% fill volume for 12 minutes.

Structural Determinants of ACE-Inhibitor Pharmacodynamics

A systematic comparison between enalapril and other ACE inhibitors clarifies the product’s positioning in clinical practice and its manufacturing-specific nuance. Unlike the lysine-containing lisinopril, which is an active diacid with a zwitterionic character that limits passive membrane permeability, enalapril maleate relies on the ethyl ester masking to achieve a human oral bioavailability of approximately 60% (fasting state, single 10 mg dose, healthy volunteers). The pharmacological lag introduced by hepatic hydrolysis delays the peak serum concentration of enalaprilat to 4–6 hours post-dose, whereas lisinopril reaches peak concentrations at 6–8 hours with no metabolic activation, and captopril—possessing a free sulfhydryl group—peaks at 1–1.5 hours but exhibits a significantly shorter elimination half-life (2 hours versus enalaprilat’s 11 hours). These kinetic distinctions are summarized in Table 2.

From a manufacturing perspective, the absence of a sulfhydryl group in enalapril maleate eliminates the need for nitrogen-flushed blister packaging commonly mandated for captopril, which reacts with atmospheric oxygen to form captopril disulfide. In contrast, enalapril maleate’s primary stability liability is the acid-catalyzed ester hydrolysis, accelerated at pH values below 3.0 in the presence of excipients like anhydrous citric acid. During wet granulation with an aqueous binder solution, the process window is critically narrow: granulation liquid temperature must be maintained below 25°C and drying inlet air temperature in the fluidized bed dryer must be set to 40°C ± 2°C to keep enalaprilat formation below 0.2% above the incoming API baseline. Trials on a Glatt GPCG 5 fluidized bed granulator at 15 kg scale confirmed that deviations beyond +3°C in drying air inlet resulted in end-of-run enalaprilat levels exceeding the compendial 0.5% threshold and in measurable dissolution slowdown (Q value at 30 minutes dropping from 95% to 78% in 0.01 N HCl medium per USP <711>, Apparatus 2, 50 rpm). Therefore, direct compression with pre-dried excipients remains the preferred route for manufacturers seeking to avoid the hydrolysis hazard entirely.

Process Validation Criteria for Direct Compression Tableting of Fixed-Dose Combinations

In formulations combining enalapril maleate with the calcium channel blocker amlodipine besylate—a common fixed-dose combination therapy—the interplay of particle size, charge, and blending sequence governs content uniformity of the low-dose components. Amlodipine besylate at 5 mg (equivalent to 6.9 mg salt) and enalapril maleate at 5 mg occupy less than 3% of a 500 mg target tablet weight; the remainder comprises a microcrystalline cellulose/dicalcium phosphate anhydrous filler system. Process validation protocols executed on a Fette 3090i rotary press ( 33-station, B-tooling) with a compression force range of 10–18 kN and a main compression roller dwell time of 30 ms demonstrate that stratification can be reduced to an acceptance value below 5.0 for both APIs only when the enalapril maleate is geometrically diluted with a premix of amlodipine besylate and microcrystalline cellulose (Avicel PH-102) in a bin blender at 10 rpm for 8 minutes before the final lubricant addition. In-line particle size analysis using a Malvern Insitec system at the press feed frame shows a bimodal distribution where the micronized enalapril (D₅₀ ~8 µm) adheres to the surface of the larger cellulose particles (D₅₀ ~120 µm), reducing the percolation tendency that otherwise leads to content non-uniformity in the first 15% of tablets discharged after a hopper refill. This observed processing window, validated across three consecutive commercial-scale batches (150 kg each), is now encoded in the company’s master batch record under ISO 9001:2015 quality management system guidelines and is submitted in the 3.2.P.3.3 module of the Common Technical Document.

Residual Solvent Control Under ICH Q3C(R8) and the Risk of N-Alkyl Impurities

The synthetic route to enalapril maleate typically proceeds via N-alkylation of L-alanyl-L-proline benzyl ester with ethyl 2-keto-4-phenylbutyrate under reductive amination conditions, followed by hydrogenolytic debenzylation and salt formation. Methanol and tetrahydrofuran are the primary process solvents, and their levels must be controlled below the PDE limits of 30 mg/day and 7.2 mg/day, respectively, translating to the previously cited specification limits for an API used at a maximum daily dose of 40 mg. Additionally, ICH M7(R2) assessment of mutagenic impurities requires that the potential N-alkyl carbamate byproduct arising from trace ethyl chloroformate used in esterification be controlled at a threshold of toxicological concern (TTC) of 1.5 µg/day, which for a 40 mg daily dose equates to an API acceptance limit of 0.0375 ppm. Validated LC-MS/MS methods with a limit of quantitation of 0.01 ppm are employed by qualified API vendors to demonstrate clearance factors exceeding 10,000 across the final recrystallization step from isopropanol/water (90:10 v/v). Failure to demonstrate this clearance has been a root cause of regulatory deficiency letters under US FDA DMF review, underscoring the imperative of robust process understanding. Published data for this specific configuration is limited, but the framework described aligns with the general strategy for ethyl ester prodrugs of dipeptide acids.

A final, unlabelled scenario considers the batch-to-batch micronization variance. Jet milling at a grinding pressure of 6 bar with a classifier speed set to 8,000 rpm on a Hosokawa Micronizer is capable of reducing the D₅₀ of enalapril maleate from 35 µm to 6–8 µm. However, the attendant increase in surface free energy, as measured by inverse gas chromatography (iGC-SEA), shifts the dispersive surface energy component from 38 mJ/m² to 48 mJ/m² and the specific acid-base parameter (K_a/K_b) ratio, correlating with a pronounced increase in the moisture uptake rate constant at 60% RH. This phenomenon tightens the allowable time between micronization and final blending to less than 72 hours under controlled 20°C/30% RH storage, beyond which the caking tendency renders the milled API unsuitable for direct compression without a deagglomeration step. This operational boundary is now an integral part of the batch record for micronized enalapril maleate used in highly hygroscopic filler matrices.